Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

GSK Investigational Site, Binghamton

GSK Investigational Site, Winston-Salem

GSK Investigational Site, Raleigh

GSK Investigational Site, Charleston

GSK Investigational Site, West Palm Beach

GSK Investigational Site, Pinellas Park

GSK Investigational Site, Birmingham

GSK Investigational Site, Huntsville

GSK Investigational Site, Bardstown

GSK Investigational Site, Louisville

GSK Investigational Site, Cleveland

GSK Investigational Site, Chicago

GSK Investigational Site, Omaha

GSK Investigational Site, Omaha

GSK Investigational Site, Omaha

GSK Investigational Site, Plano

GSK Investigational Site, Plano

GSK Investigational Site, Fort Worth

GSK Investigational Site, San Angelo

GSK Investigational Site, Tomball

GSK Investigational Site, San Antonio

GSK Investigational Site, Centennial

GSK Investigational Site, Littleton

GSK Investigational Site, Boise

GSK Investigational Site, Draper

GSK Investigational Site, South Jordan

GSK Investigational Site, Salt Lake City

GSK Investigational Site, Salt Lake City

GSK Investigational Site, Salt Lake City

GSK Investigational Site, Chandler

GSK Investigational Site, Anaheim

GSK Investigational Site, San Jose

GSK Investigational Site, Roseville

GSK Investigational Site, Sacramento

GSK Investigational Site, Sacramento

GSK Investigational Site, Wichita

GSK Investigational Site, Ponce